Key facts
- It has raised $10.0M.
- Notable investors include Phoenix Court, Firstminute Capital, Meltwind Advisory, BlueYard Capital, Jonathan Milner — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Clock.bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Clock.bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clock.bio
Operator of a stem cell research firm intended to extend and improve the standard of living by reversing the harmful effects of time in cells. The company specializes in developing novel treatments that can prevent and treat age-related diseases and decode the rejuvenation programs present in human cells to increase human healthspan, enabling humans to utilize regenerative capabilities.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2020
- Employees
- 9
- Website
- clock.bio/
- Ownership
- Privately Held (backing)
Clock.bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clock.bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clock.bio in its N-PORT filings yet. We sweep new filings monthly.